Base de dados : MEDLINE
Pesquisa : D02.886.590 [Categoria DeCS]
Referências encontradas : 13834 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1384 ir para página                         

  1 / 13834 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29214535
[Au] Autor:Mijangos L; Ziarrusta H; Olivares M; Zuloaga O; Möder M; Etxebarria N; Prieto A
[Ad] Endereço:Department of Analytical Chemistry, Faculty of Science and Technology, University of the Basque Country (UPV/EHU), P.O. Box 644, 48080, Bilbao, Spain.
[Ti] Título:Simultaneous determination of 41 multiclass organic pollutants in environmental waters by means of polyethersulfone microextraction followed by liquid chromatography-tandem mass spectrometry.
[So] Source:Anal Bioanal Chem;410(2):615-632, 2018 Jan.
[Is] ISSN:1618-2650
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:A new procedure using polyethersulfone (PES) microextraction followed by liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis was developed in this work for the simultaneous determination of 41 multiclass priority and emerging organic pollutants including herbicides, hormones, personal care products, and pharmaceuticals, among others, in seawater, wastewater treatment plant (WWTP) effluents, and estuary samples. The optimization of the analysis included two different chromatographic columns and different variables (polarity, fragmentor voltage, collision energy, and collision cell accelerator) of the mass spectrometer. In the case of PES extraction, ion strength of the water, pH, addition of EDTA, and the amount of the polymeric material were thoroughly investigated. The developed procedure was compared with a previously validated one based on a standard solid-phase extraction (SPE). In contrast to the SPE protocol, the PES method allowed a cost-efficient extraction of complex aqueous samples with lower matrix effect from 120 mL of water sample. Satisfactory and comparable apparent recovery values (80-119 and 70-131%) and method quantification limits (MQLs, 0.4-26 and 0.2-23 ng/L) were obtained for PES and SPE procedures, respectively, regardless of the matrix. Repeatability values lower than 27% were obtained. Finally, the developed methods were applied to the analysis of real samples from the Basque Country and irbesartan, valsartan, acesulfame, and sucralose were the analytes most often detected at the highest concentrations (51-1096 ng/L). Graphical abstract Forty-one multiclass pollutant determination in environmental waters by means of PES/SPE-LC-MS/MS.
[Mh] Termos MeSH primário: Herbicidas/análise
Hormônios/análise
Preparações Farmacêuticas/análise
Polímeros/química
Extração em Fase Sólida/métodos
Sulfonas/química
Espectrometria de Massas em Tandem/métodos
Poluentes Químicos da Água/análise
[Mh] Termos MeSH secundário: Cromatografia Líquida/métodos
Estuários
Limite de Detecção
Água do Mar/análise
Águas Residuais/análise
[Pt] Tipo de publicação:JOURNAL ARTICLE; VALIDATION STUDIES
[Nm] Nome de substância:
0 (Herbicides); 0 (Hormones); 0 (Pharmaceutical Preparations); 0 (Polymers); 0 (Sulfones); 0 (Waste Water); 0 (Water Pollutants, Chemical); 25667-42-9 (polyether sulfone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180309
[Lr] Data última revisão:
180309
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171208
[St] Status:MEDLINE
[do] DOI:10.1007/s00216-017-0763-2


  2 / 13834 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28946120
[Au] Autor:Zhao F; Jiang G; Wei P; Wang H; Ru S
[Ad] Endereço:Marine Life Science College, Ocean University of China, 5 Yushan Road, Qingdao, 266003 Shandong Province, PR China.
[Ti] Título:Bisphenol S exposure impairs glucose homeostasis in male zebrafish (Danio rerio).
[So] Source:Ecotoxicol Environ Saf;147:794-802, 2018 Jan.
[Is] ISSN:1090-2414
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:Bisphenol S (BPS) is a substitute of the plastic additive bisphenol A (BPA). Its concentrations detected in surface waters and urine samples are on the same order of magnitude as BPA. Human exposure to BPA has been implicated in the development of diabetes mellitus; however, whether BPS can disrupt glucose homeostasis and increase blood glucose concentration remains unclear. We extensively investigated the effects of environmentally relevant concentrations of BPS on glucose metabolism in male zebrafish (Danio rerio) and the underlying mechanisms of these effects. Male zebrafish were exposed to 1, 10, or 100µg/L of BPS for 28 d. Fasting blood glucose (FBG) levels, glycogen levels in the liver and muscle, and mRNA levels of key glucose metabolic enzymes and the activities of the encoded proteins in tissues were evaluated to assess the effect of BPS on glucose metabolism. Plasma insulin levels and expression of preproinsulin and glucagon genes in the visceral tissue were also evaluated. Compared with the control group, exposure to 1 and 10µg/L of BPS significantly increased FBG levels but decreased insulin levels. Gluconeogenesis and glycogenolysis in the liver were promoted, and glycogen synthesis in the liver and muscle and glycolysis in the muscle were inhibited. Exposure to 100µg/L of BPS did not significantly alter plasma insulin and blood glucose levels, but nonetheless pronouncedly interfered with gluconeogenesis, glycogenolysis, glycolysis, and glycogen synthesis. Our data indicates that BPS at environmentally relevant concentrations impairs glucose homeostasis of male zebrafish possibly by hampering the physiological effect of insulin; higher BPS doses also pronouncedly interfered with glucose metabolism.
[Mh] Termos MeSH primário: Glucose/metabolismo
Homeostase/efeitos dos fármacos
Fenóis/toxicidade
Sulfonas/toxicidade
Poluentes Químicos da Água/toxicidade
Peixe-Zebra/metabolismo
[Mh] Termos MeSH secundário: Animais
Relação Dose-Resposta a Droga
Glucagon/genética
Glicogênio/biossíntese
Insulina/sangue
Insulina/genética
Fígado/efeitos dos fármacos
Fígado/metabolismo
Masculino
Músculos/efeitos dos fármacos
Músculos/metabolismo
Precursores de Proteínas/sangue
Precursores de Proteínas/genética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Insulin); 0 (Phenols); 0 (Protein Precursors); 0 (Sulfones); 0 (Water Pollutants, Chemical); 61116-24-3 (preproinsulin); 80-09-1 (bis(4-hydroxyphenyl)sulfone); 9005-79-2 (Glycogen); 9007-92-5 (Glucagon); IY9XDZ35W2 (Glucose)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170926
[St] Status:MEDLINE


  3 / 13834 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29371221
[Au] Autor:Ross JS; Krumholz HM
[Ad] Endereço:Department of Internal Medicine, Yale School of Medicine, New Haven, CT, USA.
[Ti] Título:Bringing Vioxx back to market.
[So] Source:BMJ;360:k242, 2018 01 25.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Mh] Termos MeSH primário: Artralgia/tratamento farmacológico
Aprovação de Drogas
Lactonas/efeitos adversos
Retirada de Medicamento Baseada em Segurança
Sulfonas/efeitos adversos
[Mh] Termos MeSH secundário: Artralgia/etiologia
Hemofilia A/complicações
Seres Humanos
[Pt] Tipo de publicação:EDITORIAL; RESEARCH SUPPORT, NON-U.S. GOV'T; RESEARCH SUPPORT, U.S. GOV'T, P.H.S.
[Nm] Nome de substância:
0 (Lactones); 0 (Sulfones); 0QTW8Z7MCR (rofecoxib)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180306
[Lr] Data última revisão:
180306
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180127
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.k242


  4 / 13834 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29442003
[Au] Autor:Li Z; Shu J; Yang B; Xu C; Zou Y; Sun W
[Ti] Título:Evaluating the relationship between cell viability and volatile organic compound production following DMSO treatment of cultured human cells.
[So] Source:Pharmazie;71(12):727-732, 2016 12 01.
[Is] ISSN:0031-7144
[Cp] País de publicação:Germany
[La] Idioma:eng
[Ab] Resumo:Methylsulfinylmethane (dimethyl sulfoxide; DMSO) is widely used in clinical treatment and bioresearch. Moreover, there is bioconversion between methylsulfanylmethane (dimethyl sulfide; DMS), DMSO, and methylsulfonylmethane (DMSO2) in mammalian metabolism. Due to the real-time detection limits for volatile compounds, most research has focused on DMSO2 as a stable byproduct of DMSO. Therefore, details about the production of DMS as a byproduct of DMSO metabolism remain to be elucidated. Here, we report the characterization of trace-level volatile organic compounds (VOCs) produced following DMSO treatment of cultured human cells using an ultrasensitive vacuum ultraviolet photoionization mass spectrometer (VUV-PIMS). Using this approach, 24 h after DMSO treatment we detected 16.9 and 21 parts per billion by volume (ppbv) DMS in the atmosphere above the cells (headspace) within HeLa and 293T tissue culture flasks, respectively. When simultaneously exposed to 50 nM paclitaxel (PTX), 17.6 and 22.3 ppbv DMS were detected in the headspace of HeLa and 293T culture flasks, respectively. Nevertheless, at doses of PTX more or less than 50 nM, the detectable levels of DMS were reduced to as low as 8.4 ppbv. Our experimental results demonstrate that by co-administering 5 to 10 nM PTX with DMSO, it is possible to moderate the production of DMS considerably. However, at higher doses of PTX, increased apoptosis was observed that likely contributed to higher DMS production by cells.
[Mh] Termos MeSH primário: Sobrevivência Celular/efeitos dos fármacos
Dimetil Sulfóxido/farmacologia
Substâncias Protetoras/farmacologia
Compostos Orgânicos Voláteis/metabolismo
[Mh] Termos MeSH secundário: Antineoplásicos Fitogênicos/antagonistas & inibidores
Antineoplásicos Fitogênicos/toxicidade
Células Cultivadas
Células HEK293
Células HeLa
Seres Humanos
Paclitaxel/antagonistas & inibidores
Paclitaxel/toxicidade
Sulfonas
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antineoplastic Agents, Phytogenic); 0 (Protective Agents); 0 (Sulfones); 0 (Volatile Organic Compounds); 9H4PO4Z4FT (dimethyl sulfone); P88XT4IS4D (Paclitaxel); YOW8V9698H (Dimethyl Sulfoxide)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180215
[St] Status:MEDLINE
[do] DOI:10.1691/ph.2016.6075


  5 / 13834 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29175697
[Au] Autor:Li B; Zhou H; Yang G; Han F; Li Y; Gao Y; Gao J; Zhang F; Sun L
[Ad] Endereço:School of Pharmacy, Shenyang Pharmaceutical University, Wenhua Road 103, Shenyang, Liaoning Province, China; School of Pharmacy, Taishan Medical University, Changcheng Road 619, Tai'an, Shandong Province, China.
[Ti] Título:In vivo study of erysolin metabolic profile by ultra high performance liquid chromatography coupleded to Fourier transform ion cyclotron resonance mass spectrometry.
[So] Source:J Chromatogr B Analyt Technol Biomed Life Sci;1072:173-181, 2018 Jan 01.
[Is] ISSN:1873-376X
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:An ultra high performance liquid chromatography coupled to Fourier transform ion cyclotron resonance mass spectrometry (UHPLC-FT-ICR-MS) method was developed for the first time to study the in vivo metabolism of erysolin, a compound derived from cruciferous plants which has a definite effect of anti-tumor and anti-nerve injury. In this research, the chromatographic separation was performed on an ACQUITY UPLC BEH C18 column (2.1 mm×100mm, 1.7µm, Waters, USA) and eluted by a gradient program, the identification work was achieved on a Bruker ultra-high resolution spectrometer in positive ion mode. Plasma, urine, feces and bile samples were collected from rats to screen metabolites after an intragastric administration of erysolin at the dose of 100mg/kg. As a result, the parent drug and a total of six phase II metabolites were detected and preliminarily identified by analyzing their MS and MS/MS spectrometry profiles. Our results indicated that erysolin mainly metabolized via the mercapturic acid metabolic pathway, erysolin first react with glutathione to form glutathione conjugate, followed by taking off the glutamic acid and glycine to form cysteine conjugate, then the N-acetylation reaction occurs, the product would be excreted out of the body at last. In conclusion, results obtained in our study may contribute to a better understanding of the metabolism process and characteristics of erysolin in vivo, and provide an important reference for future research.
[Mh] Termos MeSH primário: Cromatografia Líquida de Alta Pressão/métodos
Espectrometria de Massas/métodos
Sulfonas/sangue
Tiocianatos/sangue
[Mh] Termos MeSH secundário: Animais
Masculino
Ratos
Ratos Sprague-Dawley
Reprodutibilidade dos Testes
Sensibilidade e Especificidade
Sulfonas/química
Sulfonas/farmacocinética
Tiocianatos/química
Tiocianatos/farmacocinética
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Sulfones); 0 (Thiocyanates); 504-84-7 (erysolin)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180221
[Lr] Data última revisão:
180221
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171128
[St] Status:MEDLINE


  6 / 13834 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29180064
[Au] Autor:Lee J; Kho Y; Kim PG; Ji K
[Ad] Endereço:Department of Environmental Health, Graduate School at Yongin University, Yongin, Gyeonggi 17092, Republic of Korea.
[Ti] Título:Exposure to bisphenol S alters the expression of microRNA in male zebrafish.
[So] Source:Toxicol Appl Pharmacol;338:191-196, 2018 01 01.
[Is] ISSN:1096-0333
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Bisphenol S (BPS), an alternative compound of bisphenol A, has been found to affect reproduction, development, and immune system. Although microRNAs (miRNAs) play an important role in many metabolic activities, whether and how they are involved in the process of BPS-induced toxicity is unknown. In the present study, BPS-induced changes in miRNAs and target gene expression in male zebrafish gonad, and the potential mechanism was investigated. Male zebrafish were exposed to 0, 5, and 50µg/L BPS for 21 d. miRNA was isolated from the gonad pool and the expression profiles of 255 known zebrafish miRNAs were analyzed using microarrays. Quantitative real-time polymerase chain reaction was used to validate the expression of several miRNAs in the microarray data. The GO term analysis revealed that miRNAs significantly affected by BPS exposure were involved in hematopoiesis, lymphoid organ development, and immune system development. Among 14 miRNAs that were significantly regulated after exposure to 5 and 50µg/L BPS, six targeted cyp19a1b gene, suggesting the role of BPS-induced toxicity via the interference with the aromatization process. Our findings provide novel insight into the epigenetic regulatory mechanisms of BPS-induced toxicity in male zebrafish, and identification of novel miRNA biomarkers for exposure to BPS.
[Mh] Termos MeSH primário: MicroRNAs/análise
Fenóis/toxicidade
Sulfonas/toxicidade
[Mh] Termos MeSH secundário: Animais
Masculino
Reação em Cadeia da Polimerase em Tempo Real
Peixe-Zebra
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (MicroRNAs); 0 (Phenols); 0 (Sulfones); 80-09-1 (bis(4-hydroxyphenyl)sulfone)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180213
[Lr] Data última revisão:
180213
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE


  7 / 13834 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29382005
[Au] Autor:Zhang H; Yang B
[Ad] Endereço:Department of Orthopedics, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), Beijing, China.
[Ti] Título:Successful treatment of pachydermoperiostosis patients with etoricoxib, aescin, and arthroscopic synovectomy: Two case reports.
[So] Source:Medicine (Baltimore);96(47):e8865, 2017 Nov.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: Pachydermoperiostosis (PDP) is a rare hereditary disorder that affects the skin and bones. PDP is characterized by periostosis, digital clubbing, and pachydermia. Previous studies demonstrated that increased prostaglandin E2 (PGE2) levels resulting from defective protein degradation pathways play a crucial role in PDP pathogenesis, and males were more commonly and severely affected than females. Moreover, nearly all PDP patients suffer from refractory arthralgia. Although several different treatment modalities are used for PDP, therapy for this disease remains challenging. PATIENTS CONCERNS: Two cases of PDP showing symptoms consistent with polyarthritis and arthralgia that mainly affected the knees and ankles. DIAGNOSES: The diagnostic criteria for PDP include digital clubbing, periostosis, and pachydermia. The 2 patients were diagnosed as PDP based on the finger clubbing, facial cutis furrowing, knee and ankle arthritis, and radiographic evidence of periosteal proliferation. INTERVENTIONS: Patient 1 had massive joint effusion that was treated by oral administration of etoricoxib and aescin combined with arthroscopic synovectomy, whereas Patient 2 had mild joint swelling and accepted only oral medication. OUTCOMES: Clinical symptoms of the 2 patients greatly improved after the treatment. During the 1-year follow-up, the patient experienced no adverse effects or recurrence. LESSONS: The therapeutic results showed that oral etoricoxib could reduce inflammation and retard progression of pachydermia, or even relieve facial skin furrowing, but had limited efficacy for arthralgia. However, oral aescin had satisfactory efficacy for arthralgia. Thus, etoricoxib combined with aescin is a safe and effective treatment for PDP. Meanwhile, arthroscopic synovectomy can be used to treat joint effusion, but had no therapeutic effect on arthralgia. Therefore, postoperative oral medications would be needed as subsequent therapy for joint problems. In conclusion, this study proposes an effective and safe treatment plan to address symptoms experienced by PDP patients.
[Mh] Termos MeSH primário: Fármacos Cardiovasculares/administração & dosagem
Inibidores de Ciclo-Oxigenase 2/administração & dosagem
Escina/administração & dosagem
Osteoartropatia Hipertrófica Primária/terapia
Piridinas/administração & dosagem
Sulfonas/administração & dosagem
Sinovectomia/métodos
[Mh] Termos MeSH secundário: Artroscopia
Terapia Combinada
Seres Humanos
Masculino
Resultado do Tratamento
Adulto Jovem
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Cardiovascular Agents); 0 (Cyclooxygenase 2 Inhibitors); 0 (Pyridines); 0 (Sulfones); 6805-41-0 (Escin); WRX4NFY03R (etoricoxib)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180209
[Lr] Data última revisão:
180209
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180201
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000008865


  8 / 13834 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29287092
[Au] Autor:Chatterjee A; Barnard J; Moravec C; Desnoyer R; Tirupula K; Karnik SS
[Ad] Endereço:Department of Molecular Cardiology, Lerner Research Institute, Cleveland Clinic, Cleveland, Ohio, United States of America.
[Ti] Título:Connective tissue growth factor dependent collagen gene expression induced by MAS agonist AR234960 in human cardiac fibroblasts.
[So] Source:PLoS One;12(12):e0190217, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Perspectives on whether the functions of MAS, a G protein-coupled receptor, are beneficial or deleterious in the heart remain controversial. MAS gene knockout reduces coronary vasodilatation leading to ischemic injury. G protein signaling activated by MAS has been implicated in progression of adaptive cardiac hypertrophy to heart failure and fibrosis. In the present study, we observed increased expression of MAS, connective tissue growth factor (CTGF) and collagen genes in failing (HF) human heart samples when compared to non-failing (NF). Expression levels of MAS are correlated with CTGF in HF and NF leading to our hypothesis that MAS controls CTGF production and the ensuing expression of collagen genes. In support of this hypothesis we show that the non-peptide MAS agonist AR234960 increases both mRNA and protein levels of CTGF via ERK1/2 signaling in HEK293-MAS cells and adult human cardiac fibroblasts. MAS-mediated CTGF expression can be specifically blocked by MAS inverse agonist AR244555 and also by MEK1 inhibition. Expression of CTGF gene was essential for MAS-mediated up-regulation of different collagen subtype genes in HEK293-MAS cells and human cardiac fibroblasts. Knockdown of CTGF by RNAi disrupted collagen gene regulation by the MAS-agonist. Our data indicate that CTGF mediates the profibrotic effects of MAS in cardiac fibroblasts. Blocking MAS-CTGF-collagen pathway should be considered for pharmacological intervention for HF.
[Mh] Termos MeSH primário: Colágeno/genética
Fator de Crescimento do Tecido Conjuntivo/metabolismo
Expressão Gênica/efeitos dos fármacos
Miócitos Cardíacos/efeitos dos fármacos
Sulfonas/uso terapêutico
[Mh] Termos MeSH secundário: Western Blotting
Células Cultivadas
Células HEK293
Seres Humanos
Proteínas Quinases Ativadas por Mitógeno/metabolismo
Miócitos Cardíacos/metabolismo
Fosforilação
Reação em Cadeia da Polimerase em Tempo Real
Sulfonas/farmacologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL
[Nm] Nome de substância:
0 (AR234960); 0 (Sulfones); 139568-91-5 (Connective Tissue Growth Factor); 9007-34-5 (Collagen); EC 2.7.11.24 (Mitogen-Activated Protein Kinases)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180207
[Lr] Data última revisão:
180207
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171230
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190217


  9 / 13834 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29320568
[Au] Autor:Feng X; Tian M; Zhang W; Mei H
[Ad] Endereço:Department of Nephrology and Rheumatology, Affiliated Hospital of Zunyi Medical College, Zunyi, Guizhou, China.
[Ti] Título:Gastrointestinal safety of etoricoxib in osteoarthritis and rheumatoid arthritis: A meta-analysis.
[So] Source:PLoS One;13(1):e0190798, 2018.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: To ascertain if etoricoxib increases the risk of gastrointestinal adverse events (GAEs) compared with placebo, diclofenac, and naproxen in the treatment of patients with osteoarthritis (OA) or rheumatoid arthritis (RA). METHODS: Studies were searched in MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials from inception to August 2017. Randomized Clinical Trials (RCTs) that compared etoricoxib with placebo and other active drug for patients with OA or RA and reported data on gastrointestinal safety (which is of interest to patients and clinicians) were included. The follow-up time window for GAEs was defined as within 28 days subsequent to the last dose of study medication. A meta-analysis was conducted using a fixed-effect model. Risk ratios (RRs) and 95% confidence intervals (CIs) were measured. RESULTS: We found nine randomized clinical trials (RCTs) that included information on gastrointestinal safety during follow-up time. Among them, five RCTs compared etoricoxib with placebo, four RCTs compared etoricoxib with diclofenac, and three RCTs compared etoricoxib with naproxen. Etoricoxib did not increase the risk of GAEs compared with placebo. Compared with diclofenac and naproxen, etoricoxib reduced the GAE risk (RR, 0.67; 95% CI, 0.59-0.76; p < 0.00001; 0.59; 0.48-0.72; < 0.00001) during follow-up time. CONCLUSIONS: In patients with OA or RA, etoricoxib did not increase the GAE risk compared with placebo, but reduced the GAE risk effectively compared with diclofenac and naproxen during follow-up time.
[Mh] Termos MeSH primário: Anti-Inflamatórios não Esteroides/efeitos adversos
Artrite Reumatoide/tratamento farmacológico
Inibidores de Ciclo-Oxigenase 2/efeitos adversos
Osteoartrite/tratamento farmacológico
Piridinas/efeitos adversos
Sulfonas/efeitos adversos
[Mh] Termos MeSH secundário: Anti-Inflamatórios não Esteroides/uso terapêutico
Inibidores de Ciclo-Oxigenase 2/uso terapêutico
Diclofenaco/efeitos adversos
Diclofenaco/uso terapêutico
Seres Humanos
Naproxeno/efeitos adversos
Naproxeno/uso terapêutico
Piridinas/uso terapêutico
Ensaios Clínicos Controlados Aleatórios como Assunto
Sulfonas/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS
[Nm] Nome de substância:
0 (Anti-Inflammatory Agents, Non-Steroidal); 0 (Cyclooxygenase 2 Inhibitors); 0 (Pyridines); 0 (Sulfones); 144O8QL0L1 (Diclofenac); 57Y76R9ATQ (Naproxen); WRX4NFY03R (etoricoxib)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180205
[Lr] Data última revisão:
180205
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180111
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0190798


  10 / 13834 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28461340
[Au] Autor:Fusco R; Gugliandolo E; Biundo F; Campolo M; Di Paola R; Cuzzocrea S
[Ad] Endereço:Department of Chemical, Biological, Pharmaceutical, and Environmental Sciences, University of Messina, Messina, Italy.
[Ti] Título:Inhibition of inflammasome activation improves lung acute injury induced by carrageenan in a mouse model of pleurisy.
[So] Source:FASEB J;31(8):3497-3511, 2017 08.
[Is] ISSN:1530-6860
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The inflammasome NLRP3 is a molecular pathway activated by a wide range of cellular insults to elicit innate immune defenses through the activation of caspase-1 and the maturation of proinflammatory cytokines, such as IL-1ß and IL-18. The expression of NRLP3 is abnormally elevated in numerous human inflammatory diseases, including pulmonary diseases. An injection of carrageenan (CAR) into the pleural cavity triggered an acute inflammatory response, leading to tissue damage, inflammatory exudates, leukocyte infiltration, and increased myeloperoxidase activity. The aim of this study was to assess the effect of the inflammasome blocking agents BAY 11-7082 (30 mg/kg, i.p.) and Brilliant Blue G (BBG) (45.5 mg/kg, i.p.) in a mouse model of CAR-induced pleurisy. Treatment with BAY 11-7082 or BBG 1 h after CAR injection attenuated pulmonary membrane thickening and polymorphonuclear leukocyte infiltration, reduced NF-κB translocation in the nucleus, and inhibited the assembly of the NRLP3/ASC/caspase-1 complex. Treatment with BAY 11-7082 or BBG also down-regulated iNOS, nitrotyrosine, and poly-ADP-ribosyl polymerase expression and inhibited CAR-induced apoptosis. Our results demonstrate that treatment with inflammasome-blocking agents can significantly reduce the development of acute CAR-induced lung injury.-Fusco, R. Gugliandolo, E., Biundo, F., Campolo, M., Di Paola, R., Cuzzocrea, S. Inhibition of inflammasome activation improves lung acute injury induced by carrageenan in a mouse model of pleurisy.
[Mh] Termos MeSH primário: Lesão Pulmonar Aguda/induzido quimicamente
Carragenina/toxicidade
Regulação da Expressão Gênica/efeitos dos fármacos
Inflamassomos/metabolismo
Pleurisia/induzido quimicamente
[Mh] Termos MeSH secundário: Lesão Pulmonar Aguda/metabolismo
Lesão Pulmonar Aguda/prevenção & controle
Animais
Citocinas/genética
Citocinas/metabolismo
Inflamassomos/efeitos dos fármacos
Inflamassomos/genética
Masculino
Camundongos
Fator 2 Relacionado a NF-E2/genética
Fator 2 Relacionado a NF-E2/metabolismo
Proteína 3 que Contém Domínio de Pirina da Família NLR/antagonistas & inibidores
Proteína 3 que Contém Domínio de Pirina da Família NLR/genética
Proteína 3 que Contém Domínio de Pirina da Família NLR/metabolismo
Nitrilos/farmacologia
Pleurisia/metabolismo
Pleurisia/prevenção & controle
Corantes de Rosanilina/farmacologia
Sulfonas/farmacologia
Superóxido Dismutase/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (3-(4-methylphenylsulfonyl)-2-propenenitrile); 0 (Cytokines); 0 (Inflammasomes); 0 (NF-E2-Related Factor 2); 0 (NLR Family, Pyrin Domain-Containing 3 Protein); 0 (Nfe2l2 protein, mouse); 0 (Nitriles); 0 (Rosaniline Dyes); 0 (Sulfones); 9000-07-1 (Carrageenan); EC 1.15.1.1 (Superoxide Dismutase); M1ZRX790SI (coomassie Brilliant Blue)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:180206
[Lr] Data última revisão:
180206
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170503
[St] Status:MEDLINE
[do] DOI:10.1096/fj.201601349R



página 1 de 1384 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde